Civica Rx: We ' re Entering the U.S. Insulin Biosimilar Business!

This morning, I woke up and unplugged my phone from its charger, and went to close Twitter (which I forgot to close last night before I went to bed) and at the top was a press release from Civica Rx. The press release is here: Civica to Manufacture and Distribute Affordable Insulinhttp://dlvr.it/SL0QZV The news was greeted as a welcome development by JDRF, Beyond Type 1 and the Helmsley Charitable Trust to name a few. The ADA said nothing formally about it as of 10:00 AM. In essence, Civica Rx says it plans to sell biosimilar versions of Lantus, Humalog and Novolog. As usual, there ' s a lot of details unpack here. Here are some details you aren ' t likely to get elsewhere. One highlight is that Civica Rx isn ' t selling anything...yet. The company expects to do so starting in 2024 assuming it encounters no unexpected approval delays. The company announced a while back that it was creating an operating unit called CivicaScript dedicated to lowering the cost of select high-cost generic medicines at the pharmacy counter. It is following a " cost-plus " model similar to others such as Mark Cuban ' sCostPlus Drug Company startup (which could also offer insulin biosimilars, but hasn ' t committed to doing so), but Civica says it will require that retailers sell its insulin biosimilars for " no more than " $30/vial, or $55 for a pack of 5 pens " . Civica already has a website for the insulin products athttps://civicainsulin.org/. Civica Rx also published a ...
Source: Scott's Web Log - Category: Endocrinology Tags: 2022 Biocon Biosimilar biosimilars Civica Rx CivicaRx insulin Viatris Source Type: blogs